SARS-CoV-2 Vaccine and Drug Discovery Services Updated at Creative Biolabs

With abundant drug and vaccine development experience over coronavirus-related research, Creative Biolabs has optimized services on SARS-CoV-2, especially protease inhibitor assay, neutralizing antibody development, and VLP vaccine development.

New York, USA – April 27, 2021 – With an unrelenting drive of scientists worldwide to fight against SARS-CoV-2, knowledge on this virus and antiviral vaccines or drugs is being upgraded continuously. As more and more potential candidates are found and developed, Creative Biolabs keeps updating its SARS-CoV-2 related vaccine and drug discovery services to offer a more comprehensive service portfolio to global clients.

• Protease Inhibitor Assay of SARS-CoV-2

Research on protease inhibitors of SARS-CoV-2 has made progress with an antiviral clinical candidate targeting the main protease of SARS-CoV-2 in Phase I clinical trials recently. Previous research shows that Indinavir (Crivivan), Nelfinavir (Viracept), and Saquinavir (Fortovase) can be candidates of SARS-CoV-2 antiviral drugs, and Creative Biolabs has been working on and has already accumulated experience in these potential candidates.

Now, Creative Biolabs extends the services to include a wide range of SARS-CoV-2 protease inhibitor assays, covering spike-pseudovirus based neutralization assay, FRET-based assay, dose-response titration, thermal shift binding assay, and counter screening assay.

• Neutralizing Antibody Development for SARS-CoV-2

Neutralizing antibodies are also a key class of specific defense against viral infections. With the advanced phage display platform, Creative Biolabs has released the antibody development service of the target, CR3022, a SARS-CoV specific human mAb, which is proved to bind potently with the RBD of SARS-CoV-2.

Services about other neutralizing antibody targets, such as CD4 and glycoprotein, are also available at Creative Biolabs and can be tailored to address clients’ specific needs.

SARS-CoV-2 VLP Vaccine Platform Based on MVA Vector

In 2020, Creative Biolabs released a VLP (virus-like particle)-based vaccine development service with a variety of VLP expression systems, such as mammalian cells (293T, CHO), yeast, recombinant vaccinia virus and baculovirus expression systems.

At present, an efficient VLP (MVA, modified vaccinia virus Ankara strain) platform based on the MVA vector has been developed, which has already been used to design several candidate vaccines available for immune evaluation in animal models. This platform exhibits advantages of durable humoral and cellular immune responses, sterile immunity by single-dose immunization, little vector immunity, self-adjuvanting, and thermostability.

More information about these services can be found on

About Creative Biolabs

Empowered by leading technology and over years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States